Atrion International Inc. has announced the successful completion of its REACHexchange™ beta testing program.

MONTREAL, Canada - Atrion International Inc. has announced the successful completion of its REACHexchange™ beta testing program. The results of the beta testing validated the ease of use and practicality of REACHexchange’s bidirectional exchange of data between Atrion’s Intelligent Authoring® (IA) application and local instances of a company’s IUCLID 5 system, the tool for registering chemical substances under the REACH legislation.

“The European Chemical Bureau’s (ECB) IUCLID 5 license agreement prohibits companies from directly interfacing a third-party system with IUCLID 5, which could potentially result in redundant and inconsistent data and in the long run affect a company’s reputation,” explained Patrick J. Lavoie, President of Atrion International. “We developed REACHexchange to enable companies to overcome this limitation, all while working within the confines of the IUCLID 5 license agreement.”